VelaShape III Device in Comparison to Cryolipolysis for Circumferential Reduction
NCT ID: NCT02143960
Last Updated: 2014-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2013-09-30
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The CoolSculpt System is a noninvasive device that reduces fat by freezing fat cells until they break apart.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Velashape III device
Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation
VelaShape III
Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
Noninvasive Cryolipolysis Device
A noninvasive device that reduces fat by freezing fat cells
CoolSculpt
Noninvasive Cryolipolysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VelaShape III
Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
CoolSculpt
Noninvasive Cryolipolysis
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Fitzpatrick Skin Type I to VI
3. Having excess fat deposits bilaterally in the waist / love-handle / flank areas.
4. BMI score is greater than 18.5 and less than 29.9 - normal to overweight, but not obese.
5. Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
6. Willingness to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.
7. If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
8. Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.
Exclusion Criteria
2. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
3. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
4. Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone.
5. Known photosensitivity.
6. Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.
7. Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction.
8. Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
9. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.
10. Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
11. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
12. Suffering from hormonal imbalance which may affect weight as per the Investigator's discretion.
13. History of significant lymphatic drainage problems or impaired circulation in the area to be treated.
14. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
15. History of keloid scarring, abnormal wound healing and / or prone to bruising.
16. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
17. Use of isotretinoin (Accutane®) within 6 months of treatment or during the study.
18. Allergy to any component of the lotion (VelaSpray Ease) used in this study.
19. Cryoglobulinemia, Paroxysmal cold hemoglobinuria, or any known sensitivity to cold such as cold urticaria or Raynaud's disease.
20. Neuropathic disorders such as post-herpetic neuralgia or diabetic neuropathy, or impaired skin sensation in the area to be treated.
21. Hernia in the area to be treated.
22. Participation in a study of another device or drug within 9 month prior to enrollment or during this study, if the treated area was involved.
23. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Syneron Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shlomit Mann
Role: STUDY_DIRECTOR
Syneron Medical Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Coleman Center for Cosmetic Dermatologic Surgery
Metairie, Louisiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DC85471
Identifier Type: -
Identifier Source: org_study_id